J1932 Lanreotide (Cipla) - CanMED: HCPCS

Return Home

Home

SEER Data & Software

Observational Research in Oncology Toolbox

Medication Information

CanMED: HCPCS

Generic Name:

Lanreotide (Cipla)

Brand Name:

Lanreotide Acetate

Strength:

1mg

HCPCS:

J1932

SEER*Rx Category:

Hormonal Therapy

Major Drug Class:

Somatostatin Analog

Minor Drug Class:

Oral (Y/N):

No

FDA Approval Year:

2021

FDA Discontinuation Year:

CMS Effective Date:

Sept. 27, 2022

CMS Discontinuation Date:

Status:

In Use